Entries by admin

4Moving Biotech announces a closing of €2M investment to implement 4P004 phase 1 clinical trial on Osteoarthritis patients

4Moving Biotech, announces that it has closed a €2M investment agreement with 4P- Pharma, SATT Lutech, French Tech Seed and business angels. 4Moving Biotech is the spin-off of 4P-Pharma focusing on the development of 4P004, a first-in-class Disease Modifying OsteoArthritis Drug (DMOAD). 4Moving Biotech intends to use the proceeds to initiate a phase I clinical trial on people […]

4Moving Biotech at the OARSI Connect 2021 online event

A poster on our latest results on 4P004 entitled « Liraglutide Has Potent Anti-inflammatory And Anti-catabolic Activity In Two Cell Types Implicated In Osteoarthritis » (#435) will be presented during the OARSI Connect online event on 2021 April 29-May 1, by Pr. Francis Berenbaum (4Moving Biotech’s CEO/CMO, Head of Rheumatology department at Saint-Antoine Hospital, and Professor of Rheumatology at Sorbonne University, in Paris, France). […]

4P-Pharma est dans l’émission “Les Grands Paris de l’Entreprise”

Revital Rattenbach, présidente et fondatrice de 4P-Pharma, a été interviewée par Céline Bosquet dans l’émission “Les Grands Paris de l’Entreprise” qui sera diffusée le lundi 15 mars 2021 à 19h30 sur Demain TV (canal 31 de la TNT) et à 17h sur BSmart TV et sur BSmart.fr. Revital présentera 4P-Pharma ainsi que nos dernières actualités […]

4P-Pharma at BIO Europe Spring 2021

Roselina Lam, our Business Development and Licensing Manager, will attend the upcoming BIO Europe Spring on March 22nd-25th, 2021, delivered digitally. Contact her via the partnering platform or by e-mail, to learn more about our pipeline and discuss future partnerships. She is looking forward to meet you there!

4Moving Biotech received the Seal of Excellence from the European Commission

4Moving Biotech, our spin-off company centered on 4P004, received the Seal of Excellence from the European Commission, for its application submitted to the Horizon 2020 Accelerator (SME instrument). This award is related to the development of 4P004, our disease modifier treatment for osteoarthritis. The Seal of Excellence is a high-quality label awarded by a panel […]

Institut de la Vision & 4P-Pharma announce a partnership for the development of an innovative therapy for retinal diseases

4P-Pharma, a clinical-stage biotechnology company and the research center Institut de la Vision (Sorbonne Université, Inserm, CNRS) establish a partnership agreement for the development of 4P020, a promising therapeutic approach for dry age-related macular degeneration (dAMD) and Stargardt disease with the support of the SATT Lutech. This drug candidate, initially studied by Dr Valerie Fontaine at the Institut de la Vision, opens […]

4P-Pharma at the Biotech Showcase 2021 online

Our chairwoman, Revital Rattenbach, will attend the Biotech Showcase, January 11th – 15th online. Contact us via the partnering platform or by e-mail to schedule a virtual meeting and discuss collaboration opportunities. For more information : https://informaconnect.com/biotech-showcase/